Thomas MacDonald, ACR 2020 – Cardiovascular safety of Febuxostat and Allopurinol in Chronic Gout: The FAST Study (Part 1)
Following concerns related to the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the cardiovascular safety of febuxostat compared with allopurinol. Here we talk to Thomas MacDonald (University of Dundee, Dundee, Scotland, UK) about the results of this study and what they mean.
The late-breaking abstract entitled ‘Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)’ was presented at ACR Convergence 2020, 5-9 November.
Part 2 of our discussion can be viewed here.
- Could you tell us a little about the cardiovascular safety concerns that have emerged with febuxostat? (0:06)
- Could you tell us about the design and findings of the FAST study? (0:49)
- What factors should be considered when choosing between febuxostat and allopurinol for patients with chronic gout? (3:11)
Disclosures: The FAST study was funded by Menarini to fulfill a European Medicines Agency regulatory commitment. Menarini received financial support from Ipsen and Teijin Pharma Ltd for this study. The University of Dundee was the legal sponsor. Menarini played no part in the running of this study. Dundee University has received funds for research from Amgen, Astellas, AstraZeneca, GSK, Menarini, Pfizer, Servier, Shire and Takeda. Thomas MacDonald has also received speaker or consultancy fees from Novartis, Takeda, Servier, Shire, Astellas, Menarini and AstraZeneca.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In Gout
Michael Pillinger, ACR 2022: An analysis of neutrophil-to-lymphocyte ratio changes in patients with uncontrolled gout receiving pegloticase therapy
Pegloticase is a urate-lowering therapy that is approved for the treatment of gout. touchIMMUNOLOGY were delighted to speak with Prof. Michael Pillinger (NYU Grossman School of Medicine, New York, NY, USA) to discuss whether urate lowering therapy impacted the neutrophil-to-lymphocyte ratio in patients with uncontrolled gout. This information is brought to you by Touch Medical […]
Michael Pillinger, ACR 2022: The neutrophil-to-lymphocyte ratio as a biomarker for gout flares
The neutrophil-to-lymphocyte ratio (NLR) is a biomarker that is increased in patients with active gout. touchIMMUNOLOGY were delighted to speak with Prof. Michael Pillinger (NYU Grossman School of Medicine, New York, NY, USA) to discuss the pathophysiology of gout flares and the rationale for the NLR as a biomarker for systemic inflammation in gout. This […]
John Botson, EULAR 2022: Pegloticase and Methotrexate Co-therapy in Gout – Findings from the MIRROR Study
The FDA has recently approved pegloticase injection co-administered with methotrexate in uncontrolled gout following the findings from the MIRROR randomized clinical trial presented at EULAR 2022. touchIMMUNOLOGY were delighted to speak with Dr. John K. Botson (Orthopedic Physicians Alaska, Anchorage, AK, USA) to discuss the rationale for combining methotrexate with pegloticase in the treatment of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!